Send this to a friend

CT backs CaroGen’s quest to fight cancer, hepatitis B

Q&A talks with Bijan Almassian, president and CEO of CaroGen, a Farmington-based bioscience company developing a hepatitis B virus (HBV) immunotherapy, using replication-proficient virus-like vesicles (VLVs) technology.

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media